Virica Biotech is a hyper-growth biotechnology company that has developed a proprietary library of Viral Sensitizers (VSE™) aimed at enhancing the production of viral medicines, including vaccines and gene therapies. By targeting innate cellular antiviral defenses, VSEs significantly improve virus manufacturing yields and therapeutic effectiveness, representing a paradigm shift in the industry. The company has evaluated its technology in over 50 applications, demonstrating its scalability and effectiveness in various viral vector manufacturing processes. Founded in 2018, Virica is positioned to address critical challenges in the production of viral medicines, especially in light of recent global health crises.
Something looks off?